Genetics Research LLC Granted Patent for Novel CRISPR-Associated Method for Nucleic Acid Enrichment

Published: Oct 09, 2018

WAKEFIELD, Mass.--(BUSINESS WIRE)-- Genetics Research LLC, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and therapeutics, announced today that the U.S. Patent and Trademark Office granted the Company U.S. Patent No. 10,081,829, entitled "Detection of targeted sequence regions.”

The patent covers a novel method for enriching sequence specific nucleic acids called Negative EnrichmentTM, in which Cas endonuclease complexes are used to protect targeted sequences of interest in the presence of exonucleases. The exonucleases degrade substantially all of the nucleic acid in a sample except for the nucleic acid of interest, leaving the nucleic acid of interest isolated and amenable to analysis.

Tony Shuber, President and COO of Genetics Research, said, “Our Negative Enrichment platform is agnostic to the size of the targeted sequence of interest, and our research team has demonstrated the ability to apply our Cas9-associated Negative Enrichment platform to multiple, sequence-specific applications. These include long DNA analysis and short fragment enrichment, such as circulating cfDNA. We have also taken advantage of the specificity associated with Cas9/sgRNA complexes and can demonstrate the ability to achieve single base discrimination by Negative Enrichment.”

The patent is available here. This is the first patent that the USPTO has granted the Company on its Negative Enrichment platform. The Company has 32 additional patents pending.

Thomas A. Shields, Chairman, CEO and a principal investor in Genetics Research, said, “I am confident that the proprietary technology we have developed at Genetics Research represents the next generation of target enrichment technologies and will have a significant impact on the research and clinical space.”

The USPTO granted patent ‘1,829 on September 25, 2018, just nine months after the January 23 filing.

About Negative Enrichment™

The efficiencies and accuracy of Genetics Research’s Negative Enrichment platform provides an effective approach to sample preparation that yields consistent results based on the specific information needed and nothing more.

About Genetics Research LLC

Genetics Research is an inventor of innovative, proprietary technologies for the development of products supporting genomic analysis in research, diagnostics, and therapeutics. Genetics Research has developed Negative Enrichment, a new, low cost and simple sequence specific enrichment technology platform. This unique CRISPR/Cas9 approach can enrich for long DNA fragments out of a complex background, and demonstrates significant economic value for NGS analysis.

More information is available at www.gen-res.com.

Contacts

Genetics Research, LLC
Tony Shuber
President and COO
Mobile: 774-573-9644
Email: aps@gen-res.com

Source: Genetics Research LLC

Back to news